Login to Your Account

Shares Dip as Veloxis Whittles Pipeline to Rejection Candidate

By Cormac Sheridan
Staff Writer

Thursday, May 24, 2012
Veloxis Pharmaceuticals A/S is betting the farm on its late-stage organ transplant rejection drug LCP-Tacro and exiting from all other development activities in an effort to stretch out its rapidly dwindling cash resources.

To continue reading subscribe now to BioWorld Today

Learn More about BioWorld Today

Already a subscriber? Sign In or Buy now to activate your subscription